Noncompliance with glaucoma medication is a familiar issue. There is no one-size-fits-all solution, but aiming for simplicity, consistency, and stability from the start of treatment could help more patients adhere to their treatment plan.
Reuters recently reported on a new wave of drugs in development that it says will shake up glaucoma treatments. When the consumer media is giving your patients direct information about eye care, are you ready to answer their questions?
Neovascular glaucoma is a potentially devastating ocular consequence of pathologic neovascularization of intraocular tissue. The symptoms include vision loss caused by both the underlying etiology (such as retinal vascular disease) as well as increased intraocular pressure (IOP), often accompanied by corneal edema, hyphema, or vitreous hemorrhage.